SAT0033 Characterization of the Multi-Biomarker Disease Activity (Vectra Da™ Algorithm) Score in a Subgroup of Patients from the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) Cohort Receiving Methotrexate

Background A multi-biomarker disease activity (MBDA) score has been shown to reflect disease activity at the molecular level in patients with rheumatoid arthritis (RA). The use of MBDA or its components to predict methotrexate (MTX) response has yet to be determined. Objectives To characterize the MBDA score in RA patients treated with MTX and its ability to predict treatment response. Methods The Epidemiological Investigation of Rheumatoid Arthritis (EIRA) cohort includes patients diagnosed with RA and symptom disease duration Results Patient baseline characteristics (n=186) were similar to those of the original large EIRA cohort with median (IQR) age 52(42-59), 72% female, 67% anti-CCP positive. At baseline the median (IQR) DAS28-ESR was 5.7 (5.0-6.2) and MBDA score was 58 (47-66). 29% of the patients were good EULAR responders, 37% moderate and 34% non-responders. When analyzing patient baseline characteristics anti-CCP negativity and male sex were associated with EULAR response to MTX treatment at 3 months, whereas BL MBDA score and BL concentrations of individual biomarkers were not. The median changes in MBDA score from BL to 3 months were (-16) for good responders, (-12) for moderate and (+2) for non-responders. Changes in MBDA scores and in concentrations of single biomarkers differentiated responders from non-responders at 3 months (MBDA Score: AUROC = 0.79, p-value 0.05). Conclusions MBDA and its biomarker components can track and differentiate the clinical response in early RA patients treated with MTX, regardless of anti-CCP status. References Curtis JR, et al., Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis Care & Research 2012 Dec; 64(12):1794-803. Disclosure of Interest W. Li Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience, A. Hensvold : None Declared, S. Saevarsdottir: None Declared, N. Defranoux Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience, L. Klareskog: None Declared, A. Catrina : None Declared